ABVX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 16.05
- P/S (TTM)
- 1623.78
- EV/EBITDA
- -12.66
Profitability & growth
- ROE (TTM)
- -157.1%
- Operating margin
- -4184.0%
- Revenue growth YoY
- 35.2%
- Dividend yield
- —
- Beta
- -0.20
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Abivax SA American Depositary Shares
Company profileAbivax SA is a clinical-stage biotechnology company committed to developing cutting-edge immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is currently undergoing clinical trials for indications such as ulcerative colitis, leveraging a distinctive strategy that combines antibody-mediated therapies with innovative proprietary compounds. With a strong pipeline and a dedicated team of experienced scientists, Abivax aims to address significant unmet medical needs, positioning itself as a compelling investment choice for institutional investors…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 7-11 BOULEVARD HAUSSMANN, PARIS, FRANCE
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
